Finder makes money from featured partners, but editorial opinions are our own.

How to buy Novartis (NVS) shares in Australia

Learn how to easily invest in Novartis shares.

Novartis AG ADR is a drug manufacturers - general business with stocks listed in the US. Novartis shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$97.9 – a decrease of 0.24% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Novartis

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Novartis. Find the share by name or ticker symbol: NVS. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novartis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$97.9, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Novartis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Novartis. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Novartis stock price (NYSE:NVS)

Use our graph to track the performance of NVS stocks over time.

Have Novartis's shares ever split?

Novartis's shares were split on a 1116:1000 basis on 9 April 2019. So if you had owned 1000 shares the day before the split, the next day you would own 1116 shares. This wouldn't directly have changed the overall worth of your Novartis shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis shares which in turn could have impacted Novartis's share price.

Novartis shares at a glance

Information last updated 2023-11-26.
52-week rangeUS$79.6389 - US$105.61
50-day moving average US$96.9794
200-day moving average US$96.9679
Target priceUS$112.75
PE ratio 25.4249
Dividend yield US$3.461 (3.57%)
Earnings per share (TTM) US$3.86

Novartis share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Novartis price performance over time

Historical closes compared with the last close of $97.9

1 week (2023-11-24) -0.24%
1 month (2023-11-02) 4.06%
3 months (2023-09-01) -2.80%
6 months (2023-06-02) -1.02%
1 year (2022-12-02) 8.79%
2 years (2021-12-02) 22.45%
3 years (2020-12-02) 6.90%
5 years (2018-11-30) 20.97%

Compare trading platforms to buy Novartis shares

1 - 6 of 6
Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
0.70%
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
US$0.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts (see link for details). T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 18 million investors.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, crypto, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Options trading, US shares, ETFs
Earn US$100 in cash vouchers when you fund your new account with US$2,000 until March 30, 2024. Plus, earn up to 5.3% p.a. interest on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 15 commission-free trades on US or ASX equities for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Novartis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Novartis under- or over-valued?

Valuing Novartis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novartis's P/E ratio

Novartis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Novartis shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Novartis's PEG ratio

Novartis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.7688. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novartis's EBITDA

Novartis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$21.6 billion (£17 billion).

The EBITDA is a measure of a Novartis's overall financial performance and is widely used to measure a its profitability.

Novartis share price volatility

Over the last 12 months, Novartis's shares have ranged in value from as little as US$79.6389 up to US$105.61. A popular way to gauge a stock's volatility is its "beta".

NVS.US volatility(beta: 0.51)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis's is 0.51. This would suggest that Novartis's shares are less volatile than average (for this exchange).

Novartis financials

Revenue TTM US$54.2 billion
Operating margin TTM 28.53%
Gross profit TTM US$36.7 billion
Return on assets TTM 8.75%
Return on equity TTM 16.45%
Profit margin 14.45%
Book value 18.567
Market capitalisation US$201.7 billion

TTM: trailing 12 months

Novartis share dividends

50%

Dividend payout ratio: 50.35% of net profits

Recently Novartis has paid out, on average, around 50.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis shareholders could enjoy a 3.57% return on their shares, in the form of dividend payments. In Novartis's case, that would currently equate to about $3.461 per share.

Novartis's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Novartis's most recent dividend payout was on 20 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 9 March 2023 (the "ex-dividend date").

Novartis overview

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site